DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Schmid P, Cortés J, Dent R. et al.
LBA8_PR – KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs. placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs. pbo as adjuvant treatment for early triple-negative breast cancer (TNBC).
Ann Oncol 2019;
30: v853-v854 Im Internet:
http://www.sciencedirect.com/science/article/pii/S0923753419603637
Access:
We do not assume any responsibility for the contents of the web pages of other providers.